Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 157Carcinoma, Intraductal, Noninfiltrating 16Breast Carcinoma In Situ 12Neoplasm Metastasis 9Ovarian Neoplasms 7Breast Neoplasms, Male 7Neoplasms 4Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Glioblastoma 3Breast Cancer Female 3Urinary Bladder Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Obesity 2Infertility 2Hot Flashes 2Fibroadenoma 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2ER+ Breast Cancer 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sleep Wake Disorders 1Sexuality 1Risk Reduction Behavior 1Rhabdoid Tumor 1Pyloric Stenosis, Hypertrophic 1Primary Breast Cancer 1

Interventions

Magnetic Resonance Spectroscopy 2pembrolizumab 1naxitamab 1abemaciclib 1Vorinostat 1Tamoxifen 1Steroids 1Specimen Handling 1Letrozole 1Imatinib Mesylate 1Hormones 1Gemcitabine 1Cyclin-Dependent Kinase Inhibitor p18 1Cyclin-Dependent Kinase Inhibitor p16 1Capecitabine 1Biopsy 116-fluoroestradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Anatomic Stage IV Breast Cancer AJCC v8 × Tamoxifen × Clear all
NCT04190056 2023-08-31

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

University of California, San Francisco

Phase 2 Terminated
1 enrolled 4 charts
Breast

Anatomic Stage IV Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡